Acute pyelonephritis
diseaseOn this page
Also known as pyelonephritis, acute
Summary
Acute pyelonephritis (MONDO:0003529) is a disease and 30 clinical trials. Top therapeutic interventions include meropenem, piperacillin, and ertapenem. A subtype of pyelonephritis — broader associated-gene and molecular evidence is on the parent page (see Disease family below).
At a glance
- Clinical trials: 30
Clinical features
No curated clinical features (Orphanet) for this disease.
Identifiers
Disease identifiers
| Field | Value |
|---|---|
| Canonical name | acute pyelonephritis |
| Mondo ID | MONDO:0003529 |
| DOID | DOID:559 |
| ICD-10-CM | N10 |
| ICD-11 | 441183088 |
| NCIT | C123215 |
| SNOMED CT | 36689008 |
| UMLS | C0520575 |
| MedGen | 636072 |
| Is cancer (heuristic) | no |
Also known as: pyelonephritis, acute
Disease family
This is a subtype of pyelonephritis. Genetic, therapeutic, and trial evidence is largely curated at the broader-term level — see the parent page for the associated-gene cohort and molecular evidence.
Classification path: disease › human disease › disease by body system or component › reproductive system disorder › female reproductive system disorder › uterine disorder › uterine inflammatory disease › pyelonephritis › acute pyelonephritis
Related subtypes (1): chronic pyelonephritis
Genetics & variants
GWAS landscape
No GWAS associations recorded — common-variant (GWAS) studies don’t cover this disease (typical for Mendelian / rare diseases). See the curated gene cohort and Mendelian overlap below.
Variant details and genetic-evidence tiers
No tiered GWAS variants or ClinVar records for this disease.
Genes & proteins
No associated-gene cohort resolved for this disease. Atlas builds the molecular and therapeutic sections — associated genes, protein families, druggability, pathways, interactions, and drug associations — by aggregating over a disease’s associated genes (resolved via GWAS / GenCC / ClinVar / CIViC), and none resolved here. This is expected for antibody-mediated, autoimmune, or otherwise non-gene-defined conditions; the curated evidence for this disease is its clinical features, GWAS susceptibility, and clinical trials (above).
Function
No pathway enrichment — requires an associated-gene cohort.
Therapeutics
No druggable-target or therapeutic data for this disease’s cohort.
Clinical trials & evidence
Clinical trials
Clinical trials: 30.
Phase distribution (across all retrieved trials)
| Phase | Trials |
|---|---|
| PHASE3 | 14 |
| PHASE2 | 7 |
| Not specified | 7 |
| PHASE4 | 1 |
| PHASE2/PHASE3 | 1 |
Top trials by phase / activity
| NCT | Phase | Status | Title |
|---|---|---|---|
| NCT04882085 | PHASE4 | COMPLETED | Efficacy and Safety of CAZ-AVI in the Treatment of Infections Due to Carbapenem-resistant G- Pathogens in Chinese Adults |
| NCT02007889 | PHASE3 | UNKNOWN | L-carnitine on the Prevention of Renal Scarring in Acute Pyelonephritis |
| NCT02166476 | PHASE3 | COMPLETED | Efficacy/Safety of Meropenem-Vaborbactam Compared to Piperacillin-Tazobactam in Adults With cUTI and AP |
| NCT02168946 | PHASE3 | COMPLETED | Efficacy, Safety, Tolerability of Vabomere Compared to Best Available Therapy in Treating Serious Infections in Adults |
| NCT02192580 | PHASE3 | UNKNOWN | Oral Omega-3 for Reduction of Kidney Scar Due to Pyelonephritis in Children |
| NCT02486627 | PHASE3 | COMPLETED | A Study of Plazomicin Compared With Meropenem for the Treatment of Complicated Urinary Tract Infection (cUTI) Including Acute Pyelonephritis (AP) |
| NCT02753946 | PHASE2/PHASE3 | COMPLETED | Safety and Efficacy of ZTI-01 (IV Fosfomycin) vs Piperacillin/Tazobactam for Treatment cUTI/AP Infections |
| NCT03477422 | PHASE3 | COMPLETED | CSE-1034 (Ceftriaxone+ Sulbactam+ EDTA) Compared to Meropenem in Complicated Urinary Tract Infections (cUTIs) Caused by ESBL Producing Gram Negative Bacteria |
| NCT03630081 | PHASE3 | UNKNOWN | Study of Cefepime-tazobactam (FEP-TAZ) in Complicated Urinary Tract Infection (cUTI) or Acute Pyelonephritis (AP) |
| NCT03788967 | PHASE3 | COMPLETED | Study to Assess the Efficacy, Safety and Pharmacokinetics of Orally Administered Tebipenem Pivoxil Hydrobromide (SPR994) Compared to Intravenous Ertapenem in Participants With Complicated Urinary Tract Infection (cUTI) or Acute Pyelonephritis (AP) |
| NCT03840148 | PHASE3 | COMPLETED | Safety and Efficacy Study of Cefepime/VNRX-5133 in Patients With Complicated Urinary Tract Infections |
| NCT04654507 | PHASE3 | UNKNOWN | Efficacy of Corticosteroids in Reducing Renal Scarring in Acute Pyelonephritis in Children |
| NCT04979806 | PHASE3 | COMPLETED | Study of Cefepime-zidebactam (FEP-ZID) in Complicated Urinary Tract Infection (cUTI) or Acute Pyelonephritis (AP) |
| NCT05887908 | PHASE3 | COMPLETED | Efficacy and Safety of Cefepime/Nacubactam or Aztreonam/Nacubactam Compared to Imipenem/Cilastatin in Subjects With Complicated Urinary Tract Infections or Acute Uncomplicated Pyelonephritis |
| NCT05905055 | PHASE3 | COMPLETED | P3 Study to Assess Efficacy and Safety of Cefepime/Nacubactam and Aztreonam/Nacubactam Versus Best Available Therapy for Adults With Infection Due to Carbapenem Resistant Enterobacterales |
| NCT06059846 | PHASE3 | COMPLETED | A Study of Oral Tebipenem Pivoxil Hydrobromide (TBP-PI-HBr) Compared to Intravenous Imipenem-cilastatin in Participants With Complicated Urinary Tract Infection (cUTI) or Acute Pyelonephritis (AP) |
| NCT06672978 | PHASE2 | RECRUITING | A Study to Evaluate the Safety, Tolerability, and Pharmacokinetics of Meropenem-Vaborbactam in Children With Complicated Urinary Tract Infection, Including Acute Pyelonephritis |
| NCT01096849 | PHASE2 | COMPLETED | A Study of Plazomicin Compared With Levofloxacin for the Treatment of Complicated Urinary Tract Infection (cUTI) and Acute Pyelonephritis (AP) |
| NCT01928433 | PHASE2 | COMPLETED | Finafloxacin for the Treatment of cUTI and/or Acute Pyelonephritis |
| NCT02537847 | PHASE2 | UNKNOWN | Sitafloxacin and Ertapenem Treatment for Acute Pyelonephritis Caused by Escherichia Coli |
| NCT03445195 | PHASE2 | COMPLETED | Evaluation of Safety and Efficacy of Intravenous Sulbactam-ETX2514 in the Treatment of Hospitalized Adults With Complicated Urinary Tract Infections |
| NCT03757234 | PHASE2 | COMPLETED | IV or IV/PO Omadacycline vs. IV/PO Levofloxacin for the Treatment of Acute Pyelonephritis |
| NCT05060419 | PHASE2 | UNKNOWN | Meropenem-FL058 Phase 2 Study in the Treatment of Complicated Urinary Tract Infections |
| NCT02034851 | Not specified | COMPLETED | Dexamethasone Administration in 1st Episode of Febrile Urinary Tract Infection |
| NCT02420366 | Not specified | COMPLETED | Study of Cases of Serious Infections Due to Carbapenem-Resistant Enterobacteriaceae |
| NCT04667195 | Not specified | COMPLETED | Clinical Characteristics of Acutely Hospitalized Adults With Acute Pyelonephritis |
| NCT04682834 | Not specified | NO_LONGER_AVAILABLE | Expanded Access Use of Sulopenem Etzadroxil/Probenecid for Complicated Urinary Tract Infection |
| NCT04686318 | Not specified | COMPLETED | Accuracy of Infection Biomarkers in the Investigation of Patients With Suspected Acute Pyelonephritis |
| NCT05674032 | Not specified | UNKNOWN | Bacterial Metallophores in the Diagnosis of Acute Pyelonephritis |
| NCT06141395 | Not specified | COMPLETED | NGS-Based Assay of Blood Samples of Sepsis Patients for Rapid Bacterial Identification |
Drugs tested across these trials (top 30)
| Molecule | Max phase | Trials referencing |
|---|---|---|
| MEROPENEM | 4 | 5 |
| PIPERACILLIN | 4 | 3 |
| ERTAPENEM | 4 | 2 |
| IMIPENEM ANHYDROUS | 4 | 2 |
| PLAZOMICIN | 4 | 2 |
| CEFEPIME | 4 | 1 |
| CILASTATIN | 4 | 1 |
| FOSFOMYCIN | 4 | 1 |
| LEVOCARNITINE | 4 | 1 |
| OMADACYCLINE | 4 | 1 |
| PROBENECID | 4 | 1 |
| SULBACTAM | 4 | 1 |
| SULOPENEM ETZADROXIL | 4 | 1 |
| NACUBACTAM | 3 | 2 |
| SITAFLOXACIN ANHYDROUS | 3 | 2 |
| OMEGA-3 FATTY ACIDS | 3 | 1 |
| TEBIPENEM PIVOXIL HYDROBROMIDE | 3 | 1 |
| CHEMBL388266 | 0 | 1 |